Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00257348
Status:
COMPLETED
Last Update Posted:
2013-02-08
First Post:
2005-11-21
Brief Title:
Capecitabine and Docetaxel in AdvancedRecurrent Cervical Cancer
Sponsor:
University of California Irvine
Organization:
University of California Irvine
Study Overview
Official Title:
A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the effectiveness and side effects of the drugs capecitabine and docetaxel in the treatment of cervical cancer Capecitabine is approved by the FDA for the treatment of breast and colon cancer Docetaxel is approved in the treatment of breast and lung cancer The use of capecitabine and docetaxel in this study for the treatment of cervical cancer is considered investigational Eligible subjects will take the drug capecitabine Xeloda by mouth twice a day every 12 hours for fourteen consecutive days followed by a 7 day rest period Subjects will also receive the drug docetaxel Taxotere intravenously in the vein every three weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2003-2976 | OTHER | University of California Irvine | None |